Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Netanel A Horowitz

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Cancers|July 14, 2023
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?Vladimir Vainstein, Batia Avni, Sigal Grisariu, et al.
Leukemia & Lymphoma|September 8, 2022
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study GroupChezi Ganzel, Svetlana Trestman, Shai Levi, et al.
Journal of Clinical Medicine|September 28, 2021
Continuous Remote Patient Monitoring Shows Early Cardiovascular Changes in COVID-19 PatientsArik Eisenkraft, Yasmin Maor, Keren Constantini, et al.
Blood|July 27, 2011
Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domainNetanel A Horowitz, Elizabeth A Blevins, Whitney M Miller, et al.
British Journal of Haematology|June 8, 2017
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patientsEldad J Dann, Osnat Bairey, Rachel Bar-Shalom, et al.
Blood Neoplasia|June 22, 2026
Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trialAdam J Olszewski, Abraham Avigdor, Sunil Babu, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
European Journal of Haematology|February 13, 2026
Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS OnsetHazim Khatib, Amit Parizat, Jabour Halloun, et al.
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
Cancer Medicine|February 24, 2024
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximabTali Shafat, Daniel Grupel, Tzvika Porges, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Cancers|July 14, 2023
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?Vladimir Vainstein, Batia Avni, Sigal Grisariu, et al.
Leukemia & Lymphoma|September 8, 2022
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study GroupChezi Ganzel, Svetlana Trestman, Shai Levi, et al.
Journal of Clinical Medicine|September 28, 2021
Continuous Remote Patient Monitoring Shows Early Cardiovascular Changes in COVID-19 PatientsArik Eisenkraft, Yasmin Maor, Keren Constantini, et al.
Blood|July 27, 2011
Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domainNetanel A Horowitz, Elizabeth A Blevins, Whitney M Miller, et al.
British Journal of Haematology|June 8, 2017
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patientsEldad J Dann, Osnat Bairey, Rachel Bar-Shalom, et al.
Blood Neoplasia|June 22, 2026
Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trialAdam J Olszewski, Abraham Avigdor, Sunil Babu, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
European Journal of Haematology|February 13, 2026
Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS OnsetHazim Khatib, Amit Parizat, Jabour Halloun, et al.
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
Cancer Medicine|February 24, 2024
An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximabTali Shafat, Daniel Grupel, Tzvika Porges, et al.
Pageof 7